Overview

Webcast ImageWebcast
Clovis Oncology, Inc. ESMO Investor / Analyst Briefing and Webcast (Replay)
09/09/17 at 12:00 p.m. ET
Clovis Oncology, Inc. ESMO Investor / Analyst Briefing and Webcast
Saturday, September 9, 2017 12:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$78.56
Change (%) Stock is Up 1.61 (2.09%)
Intraday High$78.90
Intraday Low$75.01
Volume1,906,898
Data as of 09/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
09/13/17Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet
ARIEL3 evaluated rucaparib as maintenance treatment among women with advanced ovarian cancer Study successfully achieved primary, key secondary and exploratory endpoints Company plans to submit a supplemental New Drug Application (sNDA) in the U.S. for maintenance treatment indication in ovarian cancer by the end of October 2017 BOULDER, Colo.--(BUSINESS WIRE)--Sep. 13, 2017-- Clovis O... 
Printer Friendly VersionDownload PDF
09/07/17Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017
ARIEL3 study successfully achieved its primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied (tumor BRCA-mutant, HRD and overall intent-to-treat) ARIEL3 study also successfully achieved the key secondary endpoint of improved PFS by blinded, independent central review (BICR) in all three study populations Rucaparib improved objective... 
Printer Friendly VersionDownload PDF
08/30/17Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress
Comprehensive results from Phase 3 ARIEL3 maintenance treatment trial of rucaparib in advanced ovarian cancer patients accepted as late-breaker presentation, will be highlighted in ESMO press program Posters outlining the designs of the ARIEL4 and TRITON clinical trial programs will also be presented BOULDER, Colo.--(BUSINESS WIRE)--Aug. 30, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstr... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.